New Trends in the Immunopathogenesis of Psoriasis

Acta Dermatovenerologica Croatica

Volumn 12, Issue 1, 2004, Pages 26-29

  Kaštelan, Marija ^a   Massari, Larisa Prpić ^a   Pašić, Aida ^b   Gruber, Franjo ^a  

^a KBC RIJEKA   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Cytokines; Immunopathogenesis; Keratinocytes; Psoriasis; T lymphocytes

Indexed keywords

BACTERIAL ANTIGEN; CYTOKINE;

CELL DIFFERENTIATION; CELL PROLIFERATION; HUMAN; IMMUNITY; IMMUNOPATHOGENESIS; KERATINOCYTE; LYMPHOCYTE ACTIVATION; NEUTROPHIL; PSORIASIS; REVIEW; SKIN INFLAMMATION; T LYMPHOCYTE; TH1 CELL;

HUMANS; PSORIASIS; T-LYMPHOCYTES;

EID: 1942520425     PISSN: 1330027X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Stern R. Psoriasis. Lancet 1997;350:349-53.
2. Ortonne JP. Recent developments in the understanding of the pathogenesis of psoriasis. Br J Dermatol 1999;140:1-7.
3. Nickoloff BJ. The immunologic and genetic basis of psoriasis. Arch Dermatol 1999;135:1104-10.
4. Norris DA, Travers JB, Leung DY. Lymphocyte activation in the pathogenesis of psoriasis. J Invest Dermatol 1997;109:1-4.
5. Boss JD. The pathomechanisms of psoriasis: the skin immune system and cyclosporin. Br J Dermatol 1988;118:141-55.
6. Gottlieb SL, Gilleaudeau P, Johnson R, Estes L, Woodworth TG, Gotlieb AB, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB3891L-2) suggest a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995;1:442-7.
7. Wrone-Smith T, Nickoloff BJ. Dermal injection of immunocytes induces psoriasis. J Clin Invest 1996;98:1878-87.
8. Valdimarsson H, Baker BS, Jonsdottir I, Powles A, Fry L. Psoriasis: a T-cell mediated autoimmune disease induced by streptococcal superantigens? Immunol Today 1995;16:145-9.
9. Kirby B, Griffiths CE. Psoriasis: the future. Br J Dermatol 2001;144(Suppl 58):37-43.
10. Prinz JC. Which T cells cause psoriasis? Clin Exp Dermatol 1999;24:291-5.
11. Prinz JC. Psoriasis vulgaris - a sterile antibacterial skin reaction mediated by cross-reactive T cells? An immunological view of the pathophysiology of psoriasis. Clin Exp Dermatol 2001;26:326-32.
12. Austin LM, Coven TR, Bhardwaj N, Steinman R, Krueger JG. Intraepidermal lymphocytes in psoriatic lesions are activated GMP-17(TIA-1)+CD8+CD3+ CTLs as determined by phenotypic analysis. J Cutan Pathol 1998;25:79-88.
13. Ferenczi K, Burack L, Pope M, Krueger JG, Austin LM. CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry. J Autoimmun 2000;14:63-78.
14. Karasek MA. Progress in our understanding of the biology of psoriasis. Cutis 1999;64:319-22.
15. Bata-Csorgo Z, Hammerberg C, Voorhees JJ, Cooper KD. Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture. Cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninvolved, but not normal, stem keratinocytes. J Clin Invest 1995;95:317-27.
16. Baker BS, Fry L. The immunology of psoriasis. Br J Dermatol 1992;126:1-9.
17. Leung DJ, Walsh P, Giorno R, Norris DA. A potential role for superantigens in the pathogenesis of psoriasis. J Invest Dermatol 1993;100:225-8.
18. Voorhees JJ. Psoriasis - an immunological disease. J Dermatol 1996;23:851-7.
19. Leung DY, Travers JB, Norris DA. The role of superantigens in skin diseases. J Invest Dermatol 1995;105(1 Suppl):37-42.
20. Valdimarsson H, Sigmundsdottir H, Jonsdottir I. Is psoriasis induced by streptococcal superantigens and maintained by M-protein-specific T cells that cross-react with keratin? Clin Exp Immunol 1997;107 Suppl 1:21-4.
21. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002;46:1-23.
22. Abrams JR, Kelley SL, Hayes E, Kikuchi T, Brown MJ, Kang S, et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA41g) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells and endothelial cells. J Exp Med 2000;192:705-17.
23. Berridge MJ. Lymphocyte activation in health and disease. Crit Rew Immunol 1997;17:155-78.
24. Thompson CB, Lindsten T, Ledbetter JA, Kunkel SL, Young HA, Emerson SG, et al. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc Natl Acad Sci USA 1989;86:1333-7.
25. Schlaak JF, Buslau M, Jochum W, Hermann E, Girndt M, Gallati H, et al. T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol 1994;102:145-9.
26. Peng X, Kasran A, Warmerdam PA, de Boer M, Ceuppens JL. Accessory signaling by CD40 for T cell activation: induction of Th1 and Th2 cytokines and synergy with interleukin-12 for interferon-gamma production. Eur J Immunol 1996;26:1621-7.
27. Uyemura K, Yamamura M, Fivenson DF, Modlin RL, Nickoloff BJ. The cytokine network in lesional and lesional-free psoriatic skin is characterized by a T helper type 1 cell-mediated response. J Invest Dermatol 1993;101:701-5.
28. Fuhlbrigge RC, Kieffer JD, Armerding D, Kupper TS. Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature 1997;389:978-81.
29. Robert C, Kupper TS. Inflammatory skin diseases, T cells and immune surveillance. N Engl J Med 1999;341:1817-28.
30. Raychaudhuri SP, Yiang WY, Farber EM, Schall TJ, Ruff MR, Pert CB. Upregulation of RANTES in psoriatic keratinocytes: a possible pathogenic mechanism for psoriasis. Acta Derm Venereol 1999;79:9-11.
31. Gillitzer R, Ritter U, Spandau U, Goebeler M, Brocker EB. Differential expression of GRO-α and IL-8 mRNA in psoriasis: a model for neutrophil migration and accumulation in vivo. J Invest Dermatol 1996;107:778-82.
32. Bhushan M, McLaughlin B, Weiss JB, Griffiths CE. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol 1999;141:1054-60.